Idosetrhcp
1 known investors
iDose TR (travoprost intracameral implant) is a procedural pharmaceutical implant that delivers continuous prostaglandin analog therapy into the anterior chamber to control intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Marketed by Glaukos Corporation, it is offered as an alternative to daily eye drops for interventional glaucoma treatment.
BiotechDigital HealthMedical Devices
Investors · 1
Frequently asked questions
- What does Idosetrhcp do?
- iDose TR (travoprost intracameral implant) is a procedural pharmaceutical implant that delivers continuous prostaglandin analog therapy into the anterior chamber to control intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Marketed by Glaukos Corporation, it is offered as an alternative to daily eye drops for interventional glaucoma treatment.
- Who are Idosetrhcp's investors?
- Idosetrhcp's investors include Avedro, Inc..